Immuron Limited (IMRN)
| Previous Close | 2.5300 |
| Open | 2.5350 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.5000 - 2.5420 |
| 52 Week Range | 1.4810 - 5.9600 |
| Volume | |
| Avg. Volume | 950,140 |
| Market Cap | 15.054M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings Date | Feb 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswirePresenting on the Emerging Growth Conference 70 Day 1 on May 8 Register Now
MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 70th Emerging Growth Conference on May 8 & 9, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies t
GlobeNewswireImmuron Limited to Present at the Emerging Growth Conference
MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on Wednesday, 8 May, 2024. This live, interactive online event will give exist
- GlobeNewswire
Immuron Director Resignation
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. During Stephen’s tenure, Immuron launched Travelan® into the US
